{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:05:37Z","timestamp":1779483937865,"version":"3.53.1"},"reference-count":74,"publisher":"Elsevier","isbn-type":[{"value":"9780443524349","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.apcsb.2026.01.001","type":"book-chapter","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:20:06Z","timestamp":1769631606000},"page":"37-53","source":"Crossref","is-referenced-by-count":0,"title":["VISTA as a Double-Edged immune checkpoint molecule in cancer and autoimmunity"],"prefix":"10.1016","author":[{"given":"Ali Mert","family":"Sencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: Updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Molecular Cancer"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annual Review of Pathology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treatment Reviews"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.01.001_bib4","first-page":"382","article-title":"Development of small molecule drugs targeting immune checkpoints","volume":"21","author":"Chen","year":"2024","journal-title":"Cancer Biology & Medicine"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.01.001_bib5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s10637-022-01244-4","article-title":"A small molecule inhibitor of VSIG-8 prevents its binding to VISTA","volume":"40","author":"Chen","year":"2022","journal-title":"Investigational New Drugs"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.01.001_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1466839","article-title":"VISTA in hematological malignancies: a review of the literature","volume":"15","author":"Duan","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.01.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.119966","article-title":"Intracellular and exosomal localization of the negative checkpoint regulator VISTA in immune cells","volume":"1872","author":"D\u00fcbbel","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.01.001_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/cei.13415","article-title":"VISTA: Coming of age as a multi-lineage immune checkpoint","volume":"200","author":"ElTanbouly","year":"2020","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580187","article-title":"VISTA re-programs macrophage biology through the combined regulation of tolerance and anti-inflammatory pathways","volume":"11","author":"ElTanbouly","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"6475","key":"10.1016\/bs.apcsb.2026.01.001_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib12","article-title":"VISTA: A target to manage the innate cytokine storm","volume":"11","author":"ElTanbouly","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.01.001_bib13","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1172\/JCI74589","article-title":"Coinhibitory receptor PD-1H preferentially suppresses CD4\u207a T cell-mediated immunity","volume":"124","author":"Flies","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.01.001_bib14","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.4049\/jimmunol.1402648","article-title":"Mechanistic assessment of PD-1H coinhibitory receptor-induced T cell tolerance to allogeneic antigens","volume":"194","author":"Flies","year":"2015","journal-title":"Journal of Immunology"},{"issue":"38","key":"10.1016\/bs.apcsb.2026.01.001_bib15","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1021\/jacs.0c07276","article-title":"Discovery and optimization of small-molecule ligands for V-domain Ig suppressor of T-cell activation (VISTA)","volume":"142","author":"Gabr","year":"2020","journal-title":"Journal of the American Chemical Society"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.01.001_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nature Medicine"},{"issue":"522","key":"10.1016\/bs.apcsb.2026.01.001_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1159","article-title":"PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus","volume":"11","author":"Han","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"12","key":"10.1016\/bs.apcsb.2026.01.001_bib18","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"International Journal of Cancer"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib19","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3389\/fimmu.2019.01638","article-title":"Decreased expression of negative immune checkpoint VISTA by CD4+ T cells facilitates T helper 1, T helper 17, and T follicular helper lineage differentiation in GCA","volume":"10","author":"Hid Cadena","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676181","article-title":"The role of V-domain Ig suppressor of T cell activation (VISTA) in cancer therapy: Lessons learned and the road ahead","volume":"12","author":"Hosseinkhani","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.01.001_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.148247","article-title":"Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy","volume":"7","author":"Hu","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","article-title":"VISTA: An immune regulatory protein checking tumor and immune cells in cancer immunotherapy","volume":"13","author":"Huang","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1311658","article-title":"A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors","volume":"14","author":"Iadonato","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.01.001_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"7779","key":"10.1016\/bs.apcsb.2026.01.001_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"issue":"12","key":"10.1016\/bs.apcsb.2026.01.001_bib26","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Modern Pathology: an Official Journal of the United States and Canadian Academy of Pathology, Inc"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.01.001_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102721","article-title":"Recent advances in molecular mechanisms of cancer immunotherapy","volume":"15","author":"Kciuk","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.01.001_bib28","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41598-017-01411-1","article-title":"Immune-checkpoint protein VISTA critically regulates the IL-23\/IL-17 inflammatory axis","volume":"7","author":"Li","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115492","article-title":"Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha","volume":"210","author":"Li","year":"2023","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116100","article-title":"Expression and function of VISTA on myeloid cells","volume":"222","author":"Li","year":"2024","journal-title":"Biochemical Pharmacology"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.01.001_bib32","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Research"},{"issue":"21","key":"10.1016\/bs.apcsb.2026.01.001_bib33","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12943-024-02209-2","article-title":"Metabolically activated and highly polyfunctional intratumoral VISTA(+) regulatory B cells are associated with tumor recurrence in early-stage NSCLC","volume":"24","author":"Lo Tartaro","year":"2025","journal-title":"Molecular Cancer"},{"issue":"16","key":"10.1016\/bs.apcsb.2026.01.001_bib35","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1021\/acs.biochem.4c00863","article-title":"Computational mapping of conformational dynamics and interaction hotspots of human VISTA with pH-selective antibodies","volume":"64","author":"Ly","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1086102","article-title":"VISTA expression and patient selection for immune-based anticancer therapy","volume":"14","author":"Martin","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.01.001_bib37","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain Ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Reports"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.862757","article-title":"Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction","volume":"13","author":"Mostbock","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41416-018-0313-5","article-title":"VISTA expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"British Journal of Cancer"},{"issue":"15","key":"10.1016\/bs.apcsb.2026.01.001_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24152804","article-title":"CA-170 - A potent small-molecule PD-L1 inhibitor or not?","volume":"24","author":"Musielak","year":"2019","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.01.001_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102942","article-title":"Viewing the immune checkpoint VISTA: Landscape and outcomes across cancers","volume":"9","author":"Nishizaki","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.01.001_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189351","article-title":"VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis","volume":"1880","author":"Niu","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1225081","article-title":"Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights","volume":"13","author":"Noelle","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.837097","article-title":"Macrophage differentiation and polarization regulate the release of the immune checkpoint protein V-domain Ig suppressor of T cell activation","volume":"13","author":"Noubissi Nzeteu","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s40364-024-00693-8","article-title":"A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy","volume":"12","author":"Peng","year":"2024","journal-title":"Biomarker Research"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00114","article-title":"Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: A pooled analysis of phase III trials","volume":"3","author":"Pons-Tostivint","year":"2019","journal-title":"JCO Precision Oncology"},{"issue":"18","key":"10.1016\/bs.apcsb.2026.01.001_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94308","article-title":"VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses","volume":"2","author":"Prodeus","year":"2017","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.01.001_bib48","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201601","article-title":"VISTA is an activating receptor in human monocytes","volume":"218","author":"Rogers","year":"2021","journal-title":"Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Communications Biology"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.01.001_bib50","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","article-title":"VISTA and its ligands: The next generation of promising therapeutic targets in immunotherapy","volume":"23","author":"Shekari","year":"2023","journal-title":"Cancer Cell International"},{"issue":"16","key":"10.1016\/bs.apcsb.2026.01.001_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17162636","article-title":"IGSF11-Mediated immune modulation: Unlocking a novel pathway in emerging cancer immunotherapies","volume":"17","author":"Srivastava","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib53","article-title":"Relatlimab: A novel drug targeting immune checkpoint LAG-3 in melanoma therapy","volume":"14","author":"Su","year":"2023","journal-title":"Frontiers in Pharmacology"},{"issue":"95","key":"10.1016\/bs.apcsb.2026.01.001_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi7418","article-title":"LRIG1 engages ligand VISTA and impairs tumor-specific CD8(+) T cell responses","volume":"9","author":"Ta","year":"2024","journal-title":"Science Immunology"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.01.001_bib55","article-title":"New emerging targets in cancer immunotherapy: The role of VISTA","volume":"4","author":"Tagliamento","year":"2020","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.01.001_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003382","article-title":"Rationally targeted anti-VISTA antibody that blockades the C-C\u2019 loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner","volume":"10","author":"Thakkar","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib57","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-25-0535","article-title":"Conditionally active CD28xVISTA bispecific antibodies promote myeloid-driven T-cell activation","author":"Thisted","year":"2025","journal-title":"Cancer Immunology Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib58","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/s41467-024-47256-x","article-title":"VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response","volume":"15","author":"Thisted","year":"2024","journal-title":"Nature Communications"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.869768","article-title":"PD-1 immune checkpoint blockade and PSGL-1 inhibition synergize to reinvigorate exhausted T cells","volume":"13","author":"Viramontes","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104581","article-title":"VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils","volume":"379","author":"Vivian Ma","year":"2022","journal-title":"Cellular Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"issue":"41","key":"10.1016\/bs.apcsb.2026.01.001_bib62","doi-asserted-by":"crossref","first-page":"14846","DOI":"10.1073\/pnas.1407447111","article-title":"Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity","volume":"111","author":"Wang","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.01.001_bib63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"The Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.01.001_bib64","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1038\/s41598-017-06410-w","article-title":"Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability","volume":"7","author":"Wang","year":"2017","journal-title":"Scientific Reports"},{"issue":"17","key":"10.1016\/bs.apcsb.2026.01.001_bib65","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/1535370219855970","article-title":"Considering B7-CD28 as a family through sequence and structure","volume":"244","author":"West","year":"2019","journal-title":"Experimental Biology and Medicine (Maywood)"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.563044","article-title":"The expression pattern and clinical significance of the immune checkpoint regulator VISTA in human breast cancer","volume":"11","author":"Xie","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib67","article-title":"VISTA blockade aggravates bone loss in experimental murine apical periodontitis","volume":"12","author":"Yang","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-receptor interactions of Galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"6247","key":"10.1016\/bs.apcsb.2026.01.001_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/science.1261669","article-title":"Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53","volume":"349","author":"Yoon","year":"2015","journal-title":"Science (New York, N. Y.)"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.01.001_bib70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: A mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends in Immunology"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.658488","article-title":"Terminating cancer by blocking VISTA as a novel immunotherapy: Hasta la vista, baby","volume":"11","author":"Yum","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.01.001_bib72","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1038\/s12276-024-01336-6","article-title":"VISTA-mediated immune evasion in cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Experimental & Molecular Medicine"},{"issue":"18","key":"10.1016\/bs.apcsb.2026.01.001_bib73","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1158\/0008-5472.CAN-24-4774","article-title":"A four amino acid intracellular motif of VISTA blocks growth receptor signaling in cancer cells to induce tumor suppression","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apcsb.2026.01.001_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1194421","article-title":"Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection","volume":"14","author":"Zheng","year":"2023","journal-title":"Frontiers in Immunology"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Immunomodulators - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162326000015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162326000015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:21:17Z","timestamp":1779481277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162326000015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443524349"],"references-count":74,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2026.01.001","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}